Both OC formulations suppressed C3AR1, a potential new molecular target and its downstream marker STAT3 in the brains of 5xFAD female transgenic mice, which may facilitate OC next-step development as a nutraceutical for amyloid pathology in AD. This evidence concerns the gene STAT3 and Alzheimer disease.